Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.80 |
| ▸ | ABL2 | P42684 | 2/20 | 0.76 |
| ▸ | CSF1R | P07333 | 2/20 | 0.76 |
| ▸ | GAK | O14976 | 1/20 | 0.76 |
| ▸ | MLNR | O43193 | 1/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.76 |
| ▸ | JAK2 | O60674 | 1/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.76 |
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | FYN | P06241 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | YES1 | P07947 | 1/20 | 0.76 |
| ▸ | LYN | P07948 | 1/20 | 0.76 |
| ▸ | RET | P07949 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24696408 | 0.93 | ABL1 (0.75) | ABL1ABL2CSF1RGAKMLNR | |
| SCHEMBL16241610 | 0.93 | ABL1 (0.74) | ABL1ABL2CSF1RGAKMLNR | |
| SCHEMBL18298082 | 0.93 | ABL1 (0.80) | ABL1ABL2CSF1RGAKMLNR | |
| SCHEMBL31697365 | 0.93 | ABL1 (0.80) | ABL1ABL2CSF1RGAKMLNR | |
| SCHEMBL16241698 | 0.92 | ABL1 (0.73) | ABL1ABL2CSF1RGAKMLNR | |
| SCHEMBL29889174 | 0.92 | ABL1 (0.73) | ABL1ABL2CSF1RGAKMLNR | |
| SCHEMBL29888993 | 0.91 | ABL1 (0.78) | ABL1ABL2CSF1RGAKMLNR | |
| SCHEMBL18298081 | 0.91 | ABL1 (0.78) | ABL1ABL2CSF1RGAKMLNR | |
| SCHEMBL16241445 | 0.91 | ABL1 (0.78) | ABL1ABL2CSF1RGAKMLNR | |
| SCHEMBL17696276 | 0.91 | ABL1 (0.72) | ABL1ABL2CSF1RGAKMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | APICORE, LLC (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343282-A1 | PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF | ABL1, KRAS, ROS1 | ABL1 1/4885ABL2 50/4885CSF1R 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.